Therefore, NGAL has proved an early, sensitive, non-invasive biomarker for AKI in different clinical settings such as in cardiac surgery [19,20], critical care [21,22], and kidney transplantation [23,24]. The gene discussed is LCN2; the disease is acute kidney injury.